Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through various clinical trial phases, employing cutting-edge mechanisms designed to enhance patient outcomes. Backed by a robust management team and a strong intellectual property portfolio, Sagimet is strategically positioned to capitalize on the growing market demand for effective metabolic disease therapies, making it an attractive investment proposition for institutional investors in the dynamic biotech sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -24.40% |
| Return on Assets | -16.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.15 |
| Price-to-Book | 2.65 |
| Price-to-Sales (TTM) | 52.50 |
| EV/Revenue | 0.276 |
| EV/EBITDA | -1.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.59M |
| Float | $55.78M |
| % Insiders | 3.35% |
| % Institutions | 83.09% |
Volatility is currently contracting
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026.
FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet's Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company's Series A common stock be granted on August 17, 2026 to the newly hired employees.
Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executives said during a Canaccord Genuity discussion.
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here).
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution.
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in 1x1 investor meetings at the Leerink Partners Therapeutics Forum in Boston, MA on July 15, 2026.
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reductions in cholesterol levels, suggesting the potential for a cardiovascular benefit SAN MATEO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of two posters at the European Association for the Study of the Liver (EASL) Annual Congress 2026, being held in Barcelona, Spain on May 27-30, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SGMT and any ticker you trade — then tracks every position and per-strategy win rate.
